MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY - PR Newswire
MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY PR Newswire
MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY - Yahoo Finance
MAIPL THERAPEUTICS, INC. FORMS STRATEGIC ALLIANCE WITH ENDOSURE, INC. TO FACILITATE FIRST‑IN‑HUMAN TRIAL OF NOVEL NON‑HORMONAL ENDOMETRIOSIS THERAPY Yahoo Finance
Safety and pharmacology of AMY109, a long-acting anti-interleukin-8 antibody, for endometriosis: a double-blind, randomized phase 1 trial.
To evaluate the safety and pharmacokinetics/pharmacodynamics of AMY109, an anti-interleukin-8 recycling antibody in a first-in-human phase 1 trial in healthy volunteers (HVs) and patients with endometriosis.
The Voice of Endo: Leveraging Speech for an Intelligent System That Can Forecast Illness Flare-ups.
Managing complex chronic illness is challenging due to its unpredictability. This paper explores the potential of voice for automated flare-up forecasts. We conducted a six-week speculative design study with individuals …
Creation of a rat model of ovarian endometriosis: a novel and easy approach to simulating chocolate cysts.
Ovarian endometriosis(OEM) is the most common type of endometriosis, but there is still a lack of simple and easy-to-promote animal models. Therefore, it is necessary to establish a feasible animal …